First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.

L Falchi; F Offner; D Belada; J Brody; KM Linton; Y Karimi; R Cordoba; S Snauwaert; A Abbas; LW Wang; J Wu; B Elliott; MR Clausen

First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.

L Falchi
, F Offner
, D Belada
, J Brody
, KM Linton
, Y Karimi
, R Cordoba
, S Snauwaert
, A Abbas
, LW Wang
, J Wu
, B Elliott
, MR Clausen

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	40
Issue number	16
Publication status	Published - 1 Jun 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

Falchi, L., Offner, F., Belada, D., Brody, J., Linton, KM., Karimi, Y., Cordoba, R., Snauwaert, S., Abbas, A., Wang, LW., Wu, J., Elliott, B., & Clausen, MR. (2022). First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update. Journal of Clinical Oncology, 40(16).

@article{74e3ef1a0a264a17aa21c93c5d764b8f,

title = "First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.",

author = "L Falchi and F Offner and D Belada and J Brody and KM Linton and Y Karimi and R Cordoba and S Snauwaert and A Abbas and LW Wang and J Wu and B Elliott and MR Clausen",

year = "2022",

month = jun,

day = "1",

language = "English",

volume = "40",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams \& Wilkins",

number = "16",

}

Falchi, L, Offner, F, Belada, D, Brody, J, Linton, KM, Karimi, Y, Cordoba, R, Snauwaert, S, Abbas, A, Wang, LW, Wu, J, Elliott, B & Clausen, MR 2022, 'First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.', Journal of Clinical Oncology, vol. 40, no. 16.

TY - JOUR

T1 - First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL)

T2 - Phase 1/2 data update.

AU - Falchi, L

AU - Offner, F

AU - Belada, D

AU - Brody, J

AU - Linton, KM

AU - Karimi, Y

AU - Cordoba, R

AU - Snauwaert, S

AU - Abbas, A

AU - Wang, LW

AU - Wu, J

AU - Elliott, B

AU - Clausen, MR

PY - 2022/6/1

Y1 - 2022/6/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000863680301984&DestLinkType=FullRecord&DestApp=WOS

M3 - Meeting Abstract

SN - 0732-183X

VL - 40

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16

ER -

First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.

UN SDGs

Other files and links

Cite this